Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mian Xi

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Journal of Cancer|November 21, 2017
Comparative Outcomes of Induction Chemotherapy Followed By Definitive Chemoradiotherapy versus Chemoradiotherapy Alone In Esophageal Squamous Cell CarcinomaLi-Ling Luo, Mian Xi, Ya-Di Yang, et al.
Journal of Cancer|September 27, 2014
The modified glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapyPeng Zhang, Mian Xi, Qiao-Qiao Li, et al.
Plos One|August 19, 2014
Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?Peng Zhang, Mian Xi, Lei Zhao, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 10, 2015
Polymorphisms of insulin-like growth factor binding protein-3 as a predictor for risk and patient survival in esophageal squamous cell carcinomaLei Zhao, Feng Chi, Mian Xi, et al.
Radiation Oncology (London, England)|November 27, 2014
Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alonePeng Zhang, Mian Xi, Lei Zhao, et al.
BMC Cancer|September 17, 2022
Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysisTian-Tian Gao, Jia-Hui Shan, Yu-Xian Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2026
Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trialsYizhen Fu, Shiliang Liu, Jinbin Chen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 6, 2015
Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control studyShi-Liang Liu, Hong Yang, Peng Zhang, et al.
JHEP Reports : Innovation in Hepatology|September 23, 2024
Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cmZhoutian Yang, Shiliang Liu, Li Hu, et al.
British Journal of Cancer|June 27, 2024
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II studyRuixi Wang, Shiliang Liu, Baoqing Chen, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Journal of Cancer|November 21, 2017
Comparative Outcomes of Induction Chemotherapy Followed By Definitive Chemoradiotherapy versus Chemoradiotherapy Alone In Esophageal Squamous Cell CarcinomaLi-Ling Luo, Mian Xi, Ya-Di Yang, et al.
Journal of Cancer|September 27, 2014
The modified glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapyPeng Zhang, Mian Xi, Qiao-Qiao Li, et al.
Plos One|August 19, 2014
Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?Peng Zhang, Mian Xi, Lei Zhao, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 10, 2015
Polymorphisms of insulin-like growth factor binding protein-3 as a predictor for risk and patient survival in esophageal squamous cell carcinomaLei Zhao, Feng Chi, Mian Xi, et al.
Radiation Oncology (London, England)|November 27, 2014
Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alonePeng Zhang, Mian Xi, Lei Zhao, et al.
BMC Cancer|September 17, 2022
Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysisTian-Tian Gao, Jia-Hui Shan, Yu-Xian Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2026
Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trialsYizhen Fu, Shiliang Liu, Jinbin Chen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 6, 2015
Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control studyShi-Liang Liu, Hong Yang, Peng Zhang, et al.
JHEP Reports : Innovation in Hepatology|September 23, 2024
Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cmZhoutian Yang, Shiliang Liu, Li Hu, et al.
British Journal of Cancer|June 27, 2024
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II studyRuixi Wang, Shiliang Liu, Baoqing Chen, et al.
Pageof 11